CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.
CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.